Joint Press Release:

Avergen and BioSolveIT Win One of the First PERMIDES Grants to Push Boundaries in Personalized Medicine

Martinsried, Germany and Sankt Augustin, Germany, July 25, 2017 — Avergen Pharmaceutical GmbH (APG) and BioSolveIT announce today that they are backed by a PERMIDES grant approval from the European Union to conduct their collaboration in the very challenging field of protein-protein interactions (PPIs). These ubiquitous interactions are of central importance for most diseases, notably cancer. Given their chemical nature, PPIs are extremely difficult targets for pharmaceutical research: Their relevant binding surfaces are not only very flexible, but also extremely large — which makes it difficult to find matching inhibitor molecules; in addition many of those compounds that do bind cause problems in experimental measurements.

 

Using BioSolveIT's world renowned software SeeSAR hot spots of binding are identified, and the fragment software ReCore will be adapted to the problem to generate new molecular entities in silico that are large enough yet do not contain troublesome chemical moieties. To this end, custom-designed fragments from a proprietary space of billions of possibilities shall be mined and automatically inserted or linked to other fragments, ensuring a very good mutual fit. The gigantically large pool of fragments, the so-called fragment space, will be optimized to contain the highest level of new IP and synthetic tractability. Dr. Peter Sennhenn, CEO of transMedChem, who advises to APG as a medicinal chemistry expert, summarizes: "From the past, I already have the best experiences with BioSolveIT software, and the mix of closely interacting disciplines in this project — biology, chemistry and information technology —reassures me that we will lead this project to success!".

 

In the course of the project, the widely cited docking algorithms from BioSolveIT embedded in their LeadIT suite shall be used to rapidly check for binding orientations of putative inhibitors, and using the ultra-modern scoring concept HYDE, visual feedback will give guidance not only on how but also on where to improve the molecular candidates with respect to binding and physico-chemical properties. Dr. Marcus Gastreich, Director of Application Science at BioSolveIT explains: "This software is custom-made for the medicinal chemist and mimics a Google-like approach for the detection of suitable fragments. We can therefore speed up the entire process by orders of magnitude. This frees time to let the medicinal chemist apply his/her deep synthetic and medicinal knowledge to optimize the computer proposals in real glass flasks." In fact has this fragment linking procedure has been used experimentally for classical small molecule discovery, albeit often with months of research. The computer proposes tractable molecules within seconds.

 

"It is an honor to be supported by EU funds, and we are proud to be amongst the top applicants with this very relevant research!", Dr. Marius Yildiz, APG's CEO rejoices. In fact, this first PERMIDES call resulted in a total funding of EURO 2.5M, and the new collaboration will start in August 2017.

 

About Avergen Pharmaceuticals GmbH (APG)

APG creates long-term value through internal and collaborative innovative drug discovery programs based on novel drug targets. APG is using a platform to identify and develop protein-protein interaction (PPI) inhibitors. APG is dedicated to its core oncology indications. APG is focused on drug development until phase II clinical studies. The location of the company in Munich, Germany, enables access to experienced experts in the field of drug discovery and development, as well as business development and commercialization. APG is supported by grants of the "Bayern Innovativ" Fund and recently won a European PERMIDES grant.

 

Contact

Dr. Marius Yildiz, CEO

Am Klopferspitz 19, 82152 Martinsried

Germany

Email: info@avergen.com

www.avergen.com

Phone: +49 89 23513367

 

About BioSolveIT GmbH

BioSolveIT is a globally acting medicinal chemistry, informatics and services company. BioSolveIT is highly renowned for their superior custom software solutions for affinity estimation, structure-based design, docking, flexible molecular alignment, database searching, library design, and analysis. Their visual and fast computational technologies help to innovate pharmaceutical research with a proven track record in almost all big pharma companies, amongst them AstraZeneca, F. A. Hoffmann-LaRoche, BASF, Bayer, Boehringer-Ingelheim, GSK, Novartis, Zealand Pharma, Pfizer, Sanofi, and many others. Their latest portfolio addition, SeeSAR™, roots in co-developments with Bayer, F. A. Hoffmann-LaRoche, and Hamburg University, and helps to predict and visualize binding of therapeutic molecule candidates. Profiting from a radically simple user interface, it addresses computationally inexperienced medicinal chemists and experts alike. BioSolveIT is based in Sankt Augustin, Germany and entertains a support and sales office in Seattle, USA, and several distribution partner offices in Japan, China, and India.

 

Contact

Dr. Marcus Gastreich, Director Application Science

An der Ziegelei, 79 53757 Sankt Augustin

Germany

Email: contact@biosolveit.com

www.biosolveit.com

Phone: +49 2241 25 25 0